Results 171 to 180 of about 14,735 (228)

Toxic interaction between atorvastatin and clarithromycin causing myositis and rhabdomyolysis. [PDF]

Aust Prescr
Hurlbert M, Tay T, Holloway CJ, Girgis L.   +3 more
europepmc   +1 more source

Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds. [PDF]

Malar J
Tipthara P, Kullasakboonsri R, Kobylinski KC, Tarning J.   +3 more
europepmc   +1 more source

PP33 Functional characterization of CYP2C8 promoter polymorphisms

European Journal of Cancer Supplements, 2009
openaire   +1 more source

Drug-Metabolizing Enzymes in Human Keratinocytes and In Vitro Detection of Cytochrome P450-Mediated Phenolic Lamotrigine Metabolite. [PDF]

Chem Res Toxicol
Deck PN, Müller M, Glässner A, Vogel M, Steffens M, Heubach C, Fechner G, Becker K, Weindl G, Sachs B.   +9 more
europepmc   +1 more source

Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). [PDF]

Drug Des Devel Ther
Van Kleef LA, Michel M, Alkhouri N, Brouwer WP, Schattenberg JM.   +4 more
europepmc   +1 more source

Variable expression of hepatic genes in different liver tumor cell lines: conclusions for drug testing. [PDF]

Front Cell Dev Biol
Wisniewska MJ, Wencel A, Jakubowska M, Motyl JA, Dudek K, Burzynska B, Pijanowska DG, Pluta KD.   +7 more
europepmc   +1 more source

Inhibition of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 by Sophorea Radix extracts in human liver microsomes

, 2018
Duckhoon Kim, Daeun Lim, Min Jung Kim, Su‐Jun Lee, Jae Gook Shin, Ho-Sook Kim, Jong‐Lyul Ghim, Dong‐Hyun Kim   +7 more
openalex   +2 more sources

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications. [PDF]

Curr Ther Res Clin Exp
Yu J, Argon S, Owens K, Wang Y, Ragueneau-Majlessi I.   +4 more
europepmc   +1 more source

Molecular Ancestry Across Allelic Variants of <i>SLC22A1</i>, <i>SLC22A2</i>, <i>SLC22A3</i>, <i>ABCB1</i>, <i>CYP2C8</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Mexican-Mestizo DMT2 Patients. [PDF]

Biomedicines
Ortega-Ayala A, de la Cruz CG, Dorado P, Rodrigues-Soares F, Castillo-Nájera F, LLerena A, Molina-Guarneros J.   +6 more
europepmc   +1 more source

Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors. [PDF]

Expert Rev Clin Pharmacol
Stromatt JC, Chowdhury AT, Huang KM, Hu S, Sparreboom A, Baker SD, Eisenmann ED.   +6 more
europepmc   +1 more source